Role of VHL gene mutation in human cancer

Journal of Clinical Oncology

Volumn 22, Issue 24, 2004, Pages 4991-5004

  Kim, William Y ^a   Kaelin, William G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; OXYGEN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; VHL PROTEIN, HUMAN;

ANGIOGENESIS; CELL GROWTH; CELL SURVIVAL; FAMILIAL CANCER; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HEMANGIOBLASTOMA; HUMAN; HYDROXYLATION; KIDNEY CARCINOMA; OXYGEN SENSING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE; ADRENAL TUMOR; DIFFERENTIAL DIAGNOSIS; GENETIC PREDISPOSITION; GENETICS; KIDNEY TUMOR; METABOLISM; MUTATION; PHEOCHROMOCYTOMA; PROTEIN PROCESSING;

ADRENAL GLAND NEOPLASMS; CARCINOMA, RENAL CELL; DIAGNOSIS, DIFFERENTIAL; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HIPPEL-LINDAU DISEASE; HUMANS; KIDNEY NEOPLASMS; PHENOTYPE; PHEOCHROMOCYTOMA; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 16644373473     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.05.061     Document Type: Review

References (176)

1. Collins E: Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans Ophthalmol Soc U K 14:141-149, 1894
2. Hippel Ev: Ueber eine sehr seltene erkrankung der nethaut. Graefe Arch Ophthalmol 59:83-106, 1904
3. Lindau A: Zur frage der angiomatosis retinai und ihrer hirncomplikation. Acta Ophthalmol 4:193-226, 1927
4. Davison C, Brock S, Cyke CG: Retinal and central nervous hemangioblastomatosis with visceral changes (von Hippel-Lindau's disease). Bull Neurol Inst New York 5:72-93, 1936
5. Maher ER, Kaelin WG Jr: von Hippel-Lindau disease. Medicine (Baltimore) 76:381-391, 1997
6. Seizinger BR, Rouleau GA, Ozelius LJ, et al: Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332:268-269, 1988
7. Latif F, Tory K, Gnarra J, et al: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320, 1993
8. Renbaum P, Duh FM, Latif F, et al: Isolation and characterization of the full-length 3′ untranslated region of the human von Hippel-Lindau tumor suppressor gene. Hum Genet 98:666-671, 1996
9. Iliopoulos O, Kibel A, Gray S, et al: Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1:822-826, 1995
10. Richards FM, Schofield PN, Fleming S, et al: Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 5:639-644, 1996
11. Stolle C, Glenn G, Zbar B, et al: Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 12:417-423, 1998
12. Zbar B, Kishida T, Chen F, et al: Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8:348-357, 1996
13. Chen F, Kishida T, Yao M, et al: Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Hum Mutat 5:66-75, 1995
14. Schmidt L, Duh FM, Chen F, et al: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73, 1997
15. Tomlinson IP, Alam NA, Rowan AJ, et al: Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30:406-410, 2002
16. Nickerson ML, Warren MB, Toro JR, et al: Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2:157-164, 2002
17. Pavlovich CP, Walther MM, Eyler RA, et al: Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 26:1542-1552, 2002
18. Teh BT, Giraud S, Sari NF, et al: Familial non-VHL non-papillary clear-cell renal cancer. Lancet 349:848-849, 1997
19. Maher ER, Eng C: The pressure rises: Update on the genetics of phaeochromocytoma. Hum Mol Genet 11:2347-2354, 2002
20. Baysal BE, Ferrell RE, Willett-Brozick JE, et al: Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287:848-851, 2000
21. Milunsky JM, Maher TA, Michels W, et al: Novel mutations and the emergence of a common mutation in the SDHD gene causing familial paraganglioma. Am J Med Genet 100:311-314, 2001
22. Neumann HP, Bausch B, McWhinney SR, et al: Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459-1466, 2002
23. Gnarra JR, Tory K, Weng Y, et al: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90, 1994
24. Whaley JM, Naglich J, Gelbert L, et al: Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet 55:1092-1102, 1994
25. Lee JY, Dong SM, Park WS, et al: Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res 58:504-508, 1998
26. Shuin T, Kondo K, Torigoe S, et al: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54:2852-2855, 1994
27. Foster K, Prowse A, van den Berg A, et al: Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 3:2169-2173, 1994
28. Kenck C, Wilhelm M, Bugert P, et al: Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 179:157-161, 1996
29. Gallou C, Joly D, Mejean A, et al: Mutations of the VHL gene in sporadic renal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCC. Hum Mutat 13:464-475, 1999
30. Brauch H, Weirich G, Brieger J, et al: VHL alterations in human clear cell renal cell carcinoma: Association with advanced tumor stage and a novel hot spot mutation. Cancer Res 60:1942-1948, 2000
31. Kondo K, Yao M, Yoshida M, et al: Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters. Genes Chromosomes Cancer 34:58-68, 2002
32. Igarashi H, Esumi M, Ishida H, et al: Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer 95:47-53, 2002
33. Hamano K, Esumi M, Igarashi H, et al: Biallelic inactivation of the von Hippel-Lindau tumor suppressor gene in sporadic renal cell carcinoma. J Urol 167:713-717, 2002
34. Herman JG, Latif F, Weng Y, et al: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91:9700-9704, 1994
35. Clifford SC, Prowse AH, Affara NA, et al: Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 22:200-209, 1998
36. Brauch H, Bohm J, Hofler H: [Hippel-Lindau syndrome and sporadic renal cell carcinomas. Pathogenesis, morphologic spectrum and molecular genetics]. Pathologe 16:321-327, 1995
37. Kanno H, Kondo K, Ito S, et al: Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 54:4845-4847, 1994
38. Oberstrass J, Reifenberger G, Reifenberger J, et al: Mutation of the Von Hippel-Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system. J Pathol 179:151-156, 1996
39. Tse JY, Wong JH, Lo KW, et al: Molecular genetic analysis of the von Hippel-Lindau disease tumor suppressor gene in familial and sporadic cerebellar hemangioblastomas. Am J Clin Pathol 107:459-466, 1997
40. Olschwang S, Richard S, Boisson C, et al: Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma. Hum Mutat 12:424-430, 1998
41. Glasker S, Bender BU, Apel TW, et al: Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatry 70:644-648, 2001
42. Gijtenbeek JM, Jacobs B, Sprenger SH, et al: Analysis of von hippel-lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: Possible genetic heterogeneity. J Neurosurg 97:977-982, 2002
43. Singh AD, Ahmad NN, Shields CL, et al: Solitary retinal capillary hemangioma: Lack of genetic evidence for von Hippel-Lindau disease. Ophthalmic Genet 23:21-27, 2002
44. Webster AR, Maher ER, Bird AC, et al: A clinical and molecular genetic analysis of solitary ocular angioma. Ophthalmology 106:623-629, 1999
45. Bar M, Friedman E, Jakobovitz O, et al: Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Nippel-Lindau and RET genes. Clin Endocrinol (Oxf) 47:707-712, 1997
46. Eng C, Crossey PA, Mulligan LM, et al: Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet 32:934-937, 1995
47. Hofstra RM, Stelwagen T, Stulp RP, et al: Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases. J Clin Endocrinol Metab 81:2881-2884, 1996
48. Brauch H, Hoeppner W, Jahnig H, et al: Sporadic pheochromocytomas are rarely associated with germline mutations in the VHL tumor suppressor gene or the ret protooncogene. J Clin Endocrinol Metab 82:4101-4104, 1997
49. van der Harst E, de Krijger RR, Dinjens WN, et al: Germline mutations in the vhl gene in patients presenting with phaeochromocytomas. Int J Cancer 77:337-340, 1998
50. Bender BU, Gutsche M, Glasker S, et al: Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas. J Clin Endocrinol Metab 85:4568-4574, 2000
51. Dannenberg H, De Krijger RR, van der Harst E, et al: Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas. Int J Cancer 105:190-195, 2003
52. Knudson AG Jr, Strong LC, Anderson DE: Heredity and cancer in man. Prog Med Genet 9:113-158, 1973
53. Foster K, Osborne RJ, Huddart RA, et al: Molecular genetic analysis of the von Hippel-Lindau disease (VHL) tumour suppressor gene in gonadal tumours. Eur J Cancer 31A:2392-2395, 1995
54. Zhuang Z, Emmert-Buck MR, Roth MJ, et al: Von Hippel-Lindau disease gene deletion detected in microdissected sporadic human colon carcinoma specimens. Hum Pathol 27:152-156, 1996
55. Schoenfeld A, Davidowitz EJ, Burk RD: A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci U S A 95:8817-8822, 1998
56. Iliopoulos O, Ohh M, Kaelin WG Jr: pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci U S A 95:11661-11666, 1998
57. Blankenship C, Naglich JG, Whaley JM, et al: Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene 18:1529-1535, 1999
58. Ye Y, Vasavada S, Kuzmin I, et al: Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent. Int J Cancer 78:62-69, 1998
59. Lee S, Chen DY, Humphrey JS, et al: Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci U S A 93:1770-1775, 1996
60. Lee S, Neumann M, Stearman R, et al: Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol 19:1486-1497, 1999
61. Duan DR, Humphrey JS, Chen DY, et al: Characterization of the VHL tumor suppressor gene product: Localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci U S A 92:6459-6463, 1995
62. Hergovich A, Lisztwan J, Barry R, et al: Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 5:64-70, 2003
63. Bohling T, Hatva E, Kujala M, et al: Expression of growth factors and growth factor receptors in capillary hemangioblastoma. J Neuropathol Exp Neurol 55:522-527, 1996
64. Flamme I, Krieg M, Plate KH: Upregulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha. Am J Pathol 153:25-29, 1998
65. Morii K, Tanaka R, Washiyama K, et al: Expression of vascular endothelial growth factor in capillary hemangioblastoma. Biochem Biophys Res Commun 194:749-755, 1993
66. Stratmann R, Krieg M, Haas R, et al: Putative control of angiogenesis in hemangioblastomas by the von Hippel-Lindau tumor suppressor gene. J Neuropathol Exp Neurol 56:1242-1252, 1997
67. Wizigmann-Voos S, Breier G, Risau W, et al: Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 55:1358-1364, 1995
68. Takahashi A, Sasaki H, Kim SJ, et al: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54:4233-4237, 1994
69. Brown LF, Berse B, Jackman RW, et al: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143:1255-1262, 1993
70. Burk JR, Lertora JJ, Martinez IR Jr, et al: Renal cell carcinoma with erythrocytosis and elevated erythropoietic stimulatory activity. South Med J 70:955-958, 1977
71. Golde DW, Bersch N, Cline MJ: Polycythemia vera: Hormonal modulation of erythropoiesis in vitro. Blood 49:399-405, 1977
72. Wiesener MS, Eckardt KU: Erythropoietin, tumours and the von Hippel-Lindau gene: Towards identification of mechanisms and dysfunction of oxygen sensing. Nephrol Dial Transplant 17:356-359, 2002
73. Kawafuchi JI, Shirakura T, Azuma M, et al: Hematological study on a case with cerebellar hemangioblastoma associated with erythrocytosis, with special reference to a erythropoiesis-stimulating activity present in the fluid of the cyst of tumor. Blut 20:69-75, 1970
74. Krieg M, Haas R, Brauch H, et al: Upregulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Nippel-Lindau tumor suppressor gene loss of function. Oncogene 19:5435-5543, 2000
75. Siemeister G, Weindel K, Mohrs K, et al: Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 56:2299-2301, 1996
76. Gnarra JR, Zhou S, Merrill MJ, et al: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 93:10589-10594, 1996
77. Iliopoulos O, Levy AP, Jiang C, et al: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 93:10595-10599, 1996
78. Kishida T, Stackhouse TM, Chen F, et al: Cellular proteins that bind the von Hippel-Lindau disease gene product: Mapping of binding domains and the effect of missense mutations. Cancer Res 55:4544-4548, 1995
79. Kibel A, Iliopoulos O, DeCaprio JA, et al: Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269:1444-1446, 1995
80. Duan DR, Pause A, Burgess WH, et al: Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269:1402-1406, 1995
81. Pause A, Lee S, Worrell RA, et al: The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A 94:2156-2161, 1997
82. Lonergan KM, Iliopoulos O, Ohh M, et al: Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 18:732-741, 1998
83. Kamura T, Conrad MN, Yan Q, et al: The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev 13:2928-2933, 1999
84. Bai C, Sen P, Hofmann K, et al: SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86:263-274, 1996
85. Deshaies RJ: SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 15:435-467, 1999
86. Stebbins CE, Kaelin WG Jr., Pavletich NP: Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function. Science 284:455-461, 1999
87. Iwai K, Yamanaka K, Kamura T, et al: Identification of the von HippeHindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A 96:12436-12441, 1999
88. Lisztwan J, Imbert G, Wirbelauer C, et al: The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 13:1822-1833, 1999
89. Semenza GL: HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 13:167-171, 2001
90. Maxwell PH, Wiesener MS, Chang GW, et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275, 1999
91. Kamura T, Sato S, Iwai K, et al: Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A 97:10430-10435, 2000
92. Ohh M, Park CW, Ivan M, et al: Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2:423-427, 2000
93. Tanimoto K, Makino Y, Pereira T, et al: Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. Embo J 19:4298-4309, 2000
94. Cockman ME, Masson N, Mole DR, et al: Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275:25733-25741, 2000
95. Pugh CW, O'Rourke JF, Nagao M, et al: Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J Biol Chem 272:11205-11214, 1997
96. Kallio PJ, Wilson WJ, O'Brien S, et al: Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem 274:6519-6525, 1999
97. Huang LE, Gu J, Schau M, et al: Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 95:7987-7992, 1998
98. Ivan M, Kondo K, Yang H, et al: HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292:464-468, 2001
99. Jaakkola P, Mole DR, Tian YM, et al: Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468-472, 2001
100. Yu F, White SB, Zhao Q, et al: HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A 98:9630-9635, 2001
101. Masson N, Willam C, Maxwell PH, et al: Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. Embo J 20:5197-5206, 2001
102. Maynard MA, Qi H, Chung J, et al: Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 278:11032-11040, 2003
103. Min JH, Yang H, Ivan M, et al: Structure of an HIF-1alpha-pVHL complex: Hydroxyproline recognition in signaling. Science 296:1886-1889, 2002
104. Hon WC, Wilson MI, Harlos K, et al: Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 417:975-978, 2002
105. Epstein AC, Gleadle JM, McNeill LA, et al: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54, 2001
106. Bruick RK, McKnight SL: A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294:1337-1340, 2001
107. Ivan M, Haberberger T, Gervasi DC, et al: Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A 99:13459-13464, 2002
108. Taylor MS: Characterization and comparative analysis of the EGLN gene family. Gene 275:125-132, 2001
109. Kallio PJ, Okamoto K, O'Brien S, et al: Signal transduction in hypoxic cells: Inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. Embo J 17:6573-6586, 1998
110. Ema M, Hirota K, Mimura J, et al: Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: Their stabilization and redox signal-induced interaction with CBP/p300. Embo J 18:1905-1914, 1999
111. Lando D, Peet DJ, Gorman JJ, et al: FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16:1466-1471, 2002
112. Lando D, Peet DJ, Whelan DA, et al: Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295:858-861, 2002
113. Mahon PC, Hirota K, Semenza GL: FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15:2675-2686, 2001
114. Sang N, Fang J, Srinivas V, et al: Carboxylterminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Mol Cell Biol 22:2984-2992, 2002
115. Eng C, Kiuru M, Fernandez MJ, et al: A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer 3:193-202, 2003
116. Arias-Sella Jav, J: Chief cell hyperplasia in the human carotid body at high altitudes: Physiologic and pathoogic significance. Hum Pathol 7:361-373, 1976
117. Chandel NS, Schumacker PT: Cellular oxygen sensing by mitochondria: Old questions, new insight. J Appl Physiol 88:1880-1889, 2000
118. Aravind L, Koonin EV: The DNA-repair protein ALKLK, EGL-9, and leprecan define new families of 2-oxoglutarate- and iron-dependent dioxygenases. Genome Biol 2:research0007.1-0007.8, 2001
119. Gimenez-Roqueplo AP, Favier J, Rustin P, et al: The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet 69:1186-1197, 2001
120. Gimenez-Roqueplo AP, Favier J, Rustin P, et al: Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab 87:4771-4774, 2002
121. Hoffman MA, Ohh M, Yang H, et al: Von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10:1019-1027, 2001
122. Pastore YD, Jelinek J, Ang S, et al: Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 101:1591-1595, 2003
123. Ang SO, Chen H, Hirota K, et al: Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 32:614-621, 2002
124. Elson DA, Thurston G, Huang LE, et al: Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1 alpha. Genes Dev 15:2520-2532, 2001
125. Rebar EJ, Huang Y, Hickey R, et al: Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med 8:1427-1432, 2002
126. Vincent KA, Shyu KG, Luo Y, et al: Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 102:2255-2261, 2000
127. Jiang Y, Zhang W, Kondo K, et al: Gene Expression Profiling in a Renal Cell Carcinoma Cell Line: Dissecting VHL and Hypoxia-Dependent Pathways. Mol Cancer Res 1:453-462, 2003
128. Wykoff CC, Pugh CW, Maxwell PH, et al: Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 19:6297-6305, 2000
129. Okuda H, Saitoh K, Hirai S, et al: The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J Biol Chem 276:43611-43617, 2001
130. Pal S, Claffey KP, Cohen HT, et al: Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. J Biol Chem 273:26277-26280, 1998
131. Okuda H, Hirai S, Takaki Y, et al: Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochem Biophys Res Commun 263:491-497, 1999
132. Datta K, Nambudripad R, Pal S, et al: Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J Biol Chem 275:20700-20706, 2000
133. Li Z, Wang D, Na X, et al: Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Biochem Biophys Res Commun 294:700-709, 2002
134. Li Z, Na X, Wang D, et al: Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J Biol Chem 277:4656-4662, 2002
135. Kuznetsova AV, Meller J, Schnell PO, et al: Von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc Natl Acad Sci U S A 100:2706-2711, 2003
136. Zhou MI, Wang H, Ross JJ, et al: The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1. J Biol Chem 277:39887-39898, 2002
137. Li Z, Wang D, Na X, et al: The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1 alpha transcriptional activity. Embo J 22:1857-1867, 2003
138. Ohh M, Yauch RL, Lonergan KM, et al: The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1:959-968, 1998
139. Lieubeau-Teillet B, Rak J, Jothy S, et al: Von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 58:4957-4962, 1998
140. Esteban-Barragan MA, Avila P, Alvarez-Tejado M, et al: Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions. Cancer Res 62:2929-2936, 2002
141. Koochekpour S, Jeffers M, Wang PH, et al: The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 19:5902-5912, 1999
142. Davidowitz EJ, Schoenfeld AR, Burk RD: VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol 21:865-874, 2001
143. Pause A, Lee S, Lonergan KM, et al: The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A 95:993-998, 1998
144. Bindra RS, Vasselli JR, Stearman R, et al: VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 62:3014-3019, 2002
145. Zatyka M, da Silva NF, Clifford SC, et al: Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 62:3803-3811, 2002
146. Gunaratnam L, Morley M, Franovic A, et al: HIF activates the TGF-alpha /EGF-R growth stimulatory pathway in VHL-/- renal cell carcinoma cells. J Biol Chem 278:44966-44974, 2003
147. de Paulsen N, Brychzy A, Fournier MC, et al: Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A 98:1387-1392, 2001
148. Knebelmann B, Ananth S, Cohen HT, et al: Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 58:226-231, 1998
149. Gnarra JR, Ward JM, Porter FD, et al: Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A 94:9102-9107, 1997
150. Haase VH, Glickman JN, Socolovsky M, et al: Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A 98:1583-1588, 2001
151. Zagzag D, Zhong H, Scalzitti JM, et al: Expression of hypoxia-inducible factor 1alpha in brain tumors: Association with angiogenesis, invasion, and progression. Cancer 88:2606-2618, 2000
152. Vortmeyer AO, Gnarra JR, Emmert-Buck MR, et al: Von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol 28:540-543, 1997
153. Reifenberger G, Reifenberger J, Bilzer T, et al: Coexpression of transforming growth factor-alpha and epidermal growth factor receptor in capillary hemangioblastomas of the central nervous system. Am J Pathol 147:245-250, 1995
154. Benjamin LE, Keshet E: Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A 94:8761-8766, 1997
155. Kondo K, Kim WY, Lechpammer M, et al: Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1:E83, 2003
156. Zimmer M, Doucette D, Siddiqui N, et al: Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res 2:89-95, 2004
157. Drevs J, Medinger M, Schmidt-Gersbach C, et al: Receptor tyrosine kinases: The main targets for new anticancer therapy. Curr Drug Targets 4:113-121, 2003
158. Aiello LP, George DJ, Cahill MT, et al: Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology 109:1745-1751, 2002
159. Richard S, Croisille L, Yvart J, et al: Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy. Blood 99:3851-3853, 2002
160. Rogers LR, Kaelin W, Nadler P, et al: Response of cerebellar hemangioblastomas associated with von Hippel-Lindau disease to OSI-774 (Tarceva™). Proc Am Soc Clin Oncol 21:75b, 2002 (abstr 2111)
161. Fabbro D, Garcia-Echeverria C: Targeting protein kinases in cancer therapy. Curr Opin Drug Discov Devel 5:701-712, 2002
162. Mandriota SJ, Turner KJ, Davies DR, et al: HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1:459-468, 2002
163. Lubensky IA, Gnarra JR, Bertheau P, et al: Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 149:2089-2094, 1996
164. Zhuang Z, Roth MJ, Emmert-Buck MR, et al: Detection of the von Hippel-Lindau gene deletion in cytologic specimens using microdissection and the polymerase chain reaction. Acta Cytol 38:671-675, 1994
165. Zhuang Z, Gnarra JR, Dudley CF, et al: Detection of von Hippel-Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimens. Mod Pathol 9:838-842, 1996
166. Wiesener MS, Munchenhagen PM, Berger I, et al: Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1 alpha in clear cell renal carcinomas. Cancer Res 61:5215-5222, 2001
167. Mydlo JH, Michaeli J, Cordon-Cardo C, et al: Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res 49:3407-3411, 1989
168. Kondo K, Klco J, Nakamura E, et al: Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1:237-246, 2002
169. Maranchie JK, Vasselli JR, Riss J, et al: The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1:247-255, 2002
170. Drevs J, Hofmann I, Hugenschmidt H, et al: Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60:4819-4824, 2000
171. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
172. Clifford SC, Cockman ME, Smallwood AC, et al: Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 10:1029-1038, 2001
173. Tian H, Hammer RE, Matsumoto AM, et al: The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 12:3320-3324, 1998
174. Schnell PO, Ignacak ML, Bauer AL, et al: Regulation of tyrosine hydroxylase promoter activity by the von Hippel-Lindau tumor suppressor protein and hypoxia-inducible transcription factors. J Neurochem 85:483-491, 2003
175. Kroll SL, Paulding WR, Schnell PO, et al: Von Hippel-Lindau protein induces hypoxia-regulated arrest of tyrosine hydroxylase transcript elongation in pheochromocytoma cells. J Biol Chem 274:30109-30114, 1999
176. Bauer AL, Paulding WR, Striet JB, et al: Endogenous von Hippel-Lindau tumor suppressor protein regulates catecholaminergic phenotype in PC12 cells. Cancer Res 62:1682-1687, 2002